BioCentury
ARTICLE | Finance

Ebb & Flow

November 10, 2008 8:00 AM UTC

In the largest biotech venture financing this year, cancer stem cell antibody company OncoMed received the $93 million final tranche of a B round that totaled $154 million.

New investor Nomura Phase4 participated in the financing along with existing investors. Adams Street Partners led the round, with participation from U.S. Venture Partners; Latterell Venture Partners; The Vertical Group; Morgenthaler Ventures; De Novo Ventures; Bay Partners; and GlaxoSmithKline (LSE:GSK; NYSE:GSK)...